Physician profile
Daniel Jay Tinney
NPI 1780329110
$4,347.89
in general payments reported to CMS, 2019-2025
28 companies · $1,968 in 2025
The $1,968 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $822 · 2024: $1,412 · 2025: $1,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,195 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,194.50 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $902.84 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $744.27 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $404.65 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $393.16 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $283.59 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $248.29 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $239.98 | 2022-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $139.49 | 2024-2025 | Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $130.13 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.92 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $102.56 | 2023-2025 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $68.33 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $64.17 | 2025 | |
| Insulet Corporation | $62.79 | 2025 | Omnipod |
| Almatica Pharma LLC | $47.78 | 2023 | Loreev Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $47.74 | 2025 | Ohtuvayre |
| Alkermes, INC. | $42.84 | 2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $40.74 | 2024 | |
| Collegium Pharmaceutical, INC. | $37.67 | 2025 | Jornay Pm |
| Novo Nordisk INC | $34.34 | 2023-2024 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $34.19 | 2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $31.88 | 2022 | |
| Neurocrine Biosciences, INC. | $29.19 | 2025 | |
| Dexcom, INC. | $23.43 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.71 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.57 | 2024 | |
| Electromed, INC. | $16.40 | 2025 | Smartvest |
| Phathom Pharmaceuticals, INC. | $16.24 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.